An interventional study of Ablation in the ventricles with the Adagio Medical VT Cryoablation System in Monomorphic Ventricular Tachycardia, sponsored by Adagio Medical. Completed at 7 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.
Sponsored by Adagio Medical · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies in Tachycardia, Ventricular with a site in Canada — 17 open to participants now, 19 under way, 2 of them phase 3. Tachycardia, Ventricular · Canada.
Among the 54 studies in Tachycardia, Ventricular with a site in Canada, this one is the 23rd largest by enrollment of the 39 interventional ones that give a count, is one of 7 that started in 2021, is one of 19 with no phase, and was the 38th registered.
452 studies on the registry are indexed under Tachycardia, Ventricular; 121 are open to participants now.
Browse Tachycardia, Ventricular studies →17 of the 54 studies in Tachycardia, Ventricular with a site in Canada are open now. Recruiting first, the newest first:
Adagio Medical · Sites in Canada, United States
Ages 18+
Cardurion Pharmaceuticals, Inc. · Sites in Canada, United States, France and 3 more countries
Ages 18–99
Thermedical, Inc. · Sites in Canada, United States
Ages 18+
Ottawa Heart Institute Research Corporation · Sites in Canada
University Hospital, Basel, Switzerland · Sites in Canada, United States, Austria and 13 more countries
Ages 18+
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 86 Tachycardia, Ventricular studies recruiting now, 67 (78%) set no upper age limit and 1 (1%) stops at 75 or younger; 7 take children under 18; 5 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 7 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 64 is close to the median of 70 across 281 interventional studies indexed under Tachycardia, Ventricular.
Median enrollment 130 across the 39 interventional studies, 1,735 across the 15 observational. Of the 33 that completed or were terminated, 16 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 54 have an industry lead sponsor. The 10 most frequent:
Adagio Medical is the lead sponsor of 9 studies on the registry; 2 are open to participants now.
Adagio Medical has 3 studies filed under Tachycardia, Ventricular — fewer than ten, so there is no comparison to draw.
10 of the studies in Tachycardia, Ventricular with a site in Canada that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05047198Phase 3Ottawa Heart Institute Research CorporationCatheter Ablation Versus Radio-Ablation for Ventricular Tachycardia: a Randomized Controlled Trial | 2026-12-31 |
| NCT06281977Phase 3Ottawa Heart Institute Research CorporationStudy Evaluating Dexmedetomidine in the Acute Treatment of Electrical Storm | 2027-05-08 |
| NCT04520347University of California, Los AngelesIVTCC 2.0: A Prospective Multicenter Ventricular Tachycardia Catheter Ablation Registry | 2026-12 |
| NCT05258422McGill University Health Centre/Research Institute of the McGill University Health CentreStereotactic Arrhythmia Radioablation for Ventricular Tachycardia (StAR-VT) | 2026-12-31 |
| NCT03713866John SappPeri-Procedural Transmural Electrophysiological (EP) Imaging of Scar-Related Ventricular Tachycardia | 2026-12-31 |
Add all 10 to your calendar (.ics) → With an account.
Among the 54 studies in Tachycardia, Ventricular with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A prospective, single-arm, multi-center, pre-market, clinical study designed to provide safety and performance data regarding the use of the Adagio Medical VT Cryoablation System in the treatment of ventricular tachycardia.
Study subjects will include patients who experience recurrent monomorphic VT and are scheduled for an endocardial VT ablation. Study subjects have or will have an Implantable Cardioverter Defibrillator (ICD) prior to hospital discharge following the cryoablation procedure.
A VT ablation procedure is performed by finding the abnormal ventricular heart tissue that is causing the VT and applying energy with an ablation catheter to the area. The goal is to apply energy to create a scar or destroy the tissue that causes the VT, such that VT is no longer present or inducible.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
IC 1 Male or female the ages of ≥ 18 years
IC 2 Eligible for a catheter ablation due to Ischemic and/or non-ischemic recurrent symptomatic sustained monomorphic Ventricular Tachycardia also defined as having a similar QRS configuration from beat to beat.
IC 3 Has or will be receiving an ICD prior to hospital discharge post procedure.
IC 4 to at least one AAD (Refractory is defined as an AAD not able to treat the arrhythmia satisfactorily or induces unwanted side effects).
IC 5 Subject has > 20%, confirmed by echo or comparable technique in the previous 3 months or during baseline evaluation
IC 6 Willingness, ability, and commitment to participate in baseline and follow-up evaluations for the full length of the study
IC 7 Willingness and ability to give an
Exclusion Criteria:
EC 1 Any known objective to ventricular tachycardia ablation, TEE, or anticoagulation, including but not limited to the identification of any cardiac thrombus or evidence of sepsis
EC 2 Any duration of continuous arrythmia that is not monomorphic ventricular tachycardia. Multiple monomorphic tachycardia is acceptable, but polymorphic VT is not.
EC 3 Any VT ablation within 4 weeks prior to enrollment
EC 4 More than one prior (>4 weeks) Ventricular Tachycardia ablation or prior surgical treatment for ventricular tachycardia
EC 5 Ventricular tachycardia secondary to electrolyte imbalance, active thyroid disease, or any other reversible or non-cardiac cause
EC 6 Structural heart disease as described below:
EC 7 Any previous history of cryoglobulinemia
EC 8 History of blood clotting or bleeding disease
EC 9 Any prior history of documented cerebral vascular accident (CVA), or systemic embolism (excluding a post-operative Deep Vein Thrombosis, DVT), within 6 months prior to the ablation procedure.
EC 10 Breastfeeding, pregnant, or anticipated pregnancy during study follow-up
EC 11 Current enrollment in any other study protocol where testing or results from that study may interfere with the procedure or outcome measurements for this study
EC 12 Any other condition that, in the judgment of the investigator, makes the patient a poor candidate for this procedure, the study or compliance with the protocol (includes vulnerable patient population, mental illness, addictive disease, candidate for heart transplantation, patient with ventricular assist device, or terminal illness with a less than 12 months)
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
all study subjects will receive an ablation procedure using the Adagio Medical VT Cryoablation System
Device: Ablation in the ventricles with the Adagio Medical VT Cryoablation System
The Adagio Medical VT Cryoablation System is indicated for the treatment of monomorphic ventricular tachycardia by ablation of arrhythmogenic tissue that drives and maintains these arrhythmias
Proportion of Subjects Who Are Free From Definite or Probable Device/Procedure Related Major Adverse Events (MAEs)
An analysis of the proportion of subjects who are free from definite or probable device/procedure related Major Adverse Events (MAEs) that occur during or within 30 days following the cryoablation procedure. MAEs include any of the following: * Death * Myocardial infarction * Cardiac perforation/pericardial tamponade * Cerebral infarct or systemic embolism * Major bleeding requiring transfusion * Mitral, Tricuspid or Aortic valve damage resulting in moderate or severe regurgitation * Access site complications requiring medical or surgical intervention * Pericarditis * Heart block requiring a permanent pacemaker * Other serious adverse device effects (SADEs), including TIAs, adjudicated by an independent DSMB to be probably or definitely related to the Adagio System.
Time frame: during or within 30 days following the cryoablation procedure
6-month Freedom From Sustained VT (>30 s) or Appropriate ICD Intervention (Shock or Anti-tachycardia Pacing)
The primary clinical performance endpoint is an analysis of the proportion of patients receiving a single cryoablation procedure with freedom from ventricular tachycardia lasting longer than 30 seconds or appropriate ICD intervention until the end of the 6 month follow up period.
Time frame: 6 month post cryoablation procedure
Proportion of Patients With Non-inducible Clinical VT at the Conclusion of the Ablation Procedure
The primary procedural performance endpoint is an analysis of the proportion of subjects with non-inducible clinical monomorphic VT at the conclusion of the initial cryoablation procedure.
Time frame: at the end of the cryoablation procedure
64 subjects were enrolled.
| Milestone | Ablation in the Ventricle With the Adagio VT Cryoablation System |
|---|---|
| Started | 64 |
| Completed | 64 |
| Not completed | 0 |
An analysis of the proportion of subjects who are free from definite or probable device/procedure related Major Adverse Events (MAEs) that occur during or within 30 days following the cryoablation procedure. MAEs include any of the following: * Death * Myocardial infarction * Cardiac perforation/pericardial tamponade * Cerebral infarct or systemic embolism * Major bleeding requiring transfusion * Mitral, Tricuspid or Aortic valve damage resulting in moderate or severe regurgitation * Access site complications requiring medical or surgical intervention * Pericarditis * Heart block requiring a permanent pacemaker * Other serious adverse device effects (SADEs), including TIAs, adjudicated by an independent DSMB to be probably or definitely related to the Adagio System.
| Participants | Ablation in the Ventricle With the Adagio VT Cryoablation System |
|---|---|
| Proportion of Subjects Who Are Free From Definite or Probable Device/Procedure Related Major Adverse Events (MAEs) | 0 |
The primary clinical performance endpoint is an analysis of the proportion of patients receiving a single cryoablation procedure with freedom from ventricular tachycardia lasting longer than 30 seconds or appropriate ICD intervention until the end of the 6 month follow up period.
| percentage of participants | Ablation in the Ventricle With the Adagio VT Cryoablation System |
|---|---|
| 6-month Freedom From Sustained VT (>30 s) or Appropriate ICD Intervention (Shock or Anti-tachycardia Pacing) | 60.3 |
The primary procedural performance endpoint is an analysis of the proportion of subjects with non-inducible clinical monomorphic VT at the conclusion of the initial cryoablation procedure.
| percentage of participants | Ablation in the Ventricle With the Adagio VT Cryoablation System |
|---|---|
| Proportion of Patients With Non-inducible Clinical VT at the Conclusion of the Ablation Procedure | 94.4 |
Collected over 12-month. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ablation in the Ventricle With the Adagio VT Cryoablation System | 1/64 (1.6%) | 4/64 (6.3%) | 0/64 (0%) |
| Event | Ablation in the Ventricle With the Adagio VT Cryoablation System |
|---|---|
| Pericardial effusionCardiac disorders | 2/64 |
| Asymptomatic ventricular pseudo-aneurysmCardiac disorders | 1/64 |
| Hemodynamic instabilityCardiac disorders | 1/64 |
| Age, Continuous(years) | Ablation in the Ventricle With the Adagio VT Cryoablation System |
|---|---|
| Mean | 67 ± 11 |
| Sex: Female, Male(Participants) | Ablation in the Ventricle With the Adagio VT Cryoablation System |
|---|---|
| Female | 3 |
| Male | 61 |
| Race and Ethnicity Not Collected(Participants) | Ablation in the Ventricle With the Adagio VT Cryoablation System |
|---|
| Left Ventricular Ejection Fraction (LVEF)(%) | Ablation in the Ventricle With the Adagio VT Cryoablation System |
|---|---|
| Mean | 35 ± 10 |
Plan to share: No
Ran from May 2021 to primary completion in Jun 2024, 37 months.
Results were first posted in Oct 2026, 2 years 3 months after primary completion.
Of 40 industry-sponsored interventional studies with no phase under Tachycardia, Ventricular, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 52. This study's 37 months is above that.
Counting every sponsor, half of 126 studies reached it within 36 months; a quarter within 20 and three quarters within 66.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Adagio Medical